clinical trial · NCT04672941
Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece
Boehringer Ingelheim·—·completed·n = 1,396
Pulmonary Disease, Chronic ObstructiveTiotropium bromide plus Olodaterol
brief summary
The primary objective of this non-interventional study (NIS) is to evaluate changes within 3 months in quality of life according to health status evaluated with the COPD Assessment Test (CAT) in COPD patients who have recently switched (within one week) from tiotropium monotherapy (Spiriva® Handihaler®) to dual therapy with tiotropium bromide plus olodaterol (Spiolto® Respimat®), in the Greek private and public sector pulmonary offices and clinics.
started
Feb 16, 2021
primary completion
Feb 21, 2022
completion
Feb 21, 2022
last updated
Jun 25, 2024
official title
Quality of Life and Preference of COPD Patients After Switching From Tiotropium Monotherapy (Spiriva® Handihaler®) to Dual Therapy With Tiotropium Bromide Plus Olodaterol (Spiolto® Respimat®) Under Real Life Conditions in Greece (ELLACTO II Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol